Intralytix clin trial grant shigella
US biotech company Intralytix was just awarded a multimillion dollar grant from NIAID to perform a phase 1/2a clinicial trial to assess safety and efficacy of phage therapy against Shigella.
Topics
US biotech company Intralytix was just awarded a multimillion dollar grant from NIAID to perform a phase 1/2a clinicial trial to assess safety and efficacy of phage therapy against Shigella.